Lyell Immunopharma (LYEL) Enterprise Value Growth (3y) (2023 - 2026)

Lyell Immunopharma (LYEL) Enterprise Value Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Lyell Immunopharma 298.14 Mn 298.14 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 25.44%
Dec 31, 2025 27.18%
Sep 30, 2025 20.99%
Jun 30, 2025 24.98%
Mar 31, 2025 21.13%
Dec 31, 2024 15.53%
Sep 30, 2024 10.71%
Jun 30, 2024 15.86%
Mar 31, 2024 -29.14%
Dec 31, 2023 3.75%
Sep 30, 2023 -62.19%
Jun 30, 2023 -34.21%